Mustang Bio, Inc. (MBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
MBIO Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for MBIO is 0 -- better than only 6.93% of US stocks.
- MBIO's went public 2.59 years ago, making it older than merely 6.99% of listed US stocks we're tracking.
- As for revenue growth, note that MBIO's revenue has grown -200% over the past 12 months; that beats the revenue growth of merely 0.12% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Mustang Bio Inc, a group of peers worth examining would be ABEO, CNAT, MGEN, CTMX, and UMRX.
- MBIO's SEC filings can be seen here. And to visit Mustang Bio Inc's official web site, go to www.mustangbio.com.
MBIO Stock Price Chart Interactive Chart >
MBIO Price/Volume Stats
|Current price||$1.09||52-week high||$4.89|
|Prev. close||$1.07||52-week low||$1.01|
|Day high||$1.10||Avg. volume||1,014,416|
|50-day MA||$1.76||Dividend yield||N/A|
|200-day MA||$2.61||Market Cap||101.84M|
Mustang Bio, Inc. (MBIO) Company Bio
Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.
Most Popular Stories View All
MBIO Latest News Stream
|Loading, please wait...|
MBIO Latest Social Stream
View Full MBIO Social Stream
Latest MBIO News From Around the Web
Below are the latest news stories about Mustang Bio Inc that investors may wish to consider to help them evaluate MBIO as an investment opportunity.
The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Drug (IND) application for MB-207 in patients with X-linked severe combined immunodeficiency (XSCID). The application was submitted to initiate a pivotal Phase 2 study to assess MB-207 (lentiviral gene therapy) in patients who have been previously treated with a hematopoietic stem cell transplantation, and for whom re-treatment is indicated. The FDA has
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
WORCESTER, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a hold, pending Chemistry, Manufacturing and Controls (“CMC”) clearance, on the Company’s Investigational New Drug
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic l
WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2022. Details of the events are as follows:
HC Wainwright reiterated their buy rating on shares of Mustang Bio (NASDAQ:MBIO) in a research note issued to investors on Friday, TipRanks reports. The brokerage currently has a $7.00 price target on the stock. Other analysts have also issued research reports about the stock. BTIG Research reiterated a buy rating and issued a $11.00 price  The post HC Wainwright Reaffirms Buy Rating for Mustang Bio (NASDAQ:MBIO) appeared first on ETF Daily News .
MBIO Price Returns